Literature DB >> 23484969

Aminoacyl-tRNA synthetase-interacting multi-functional protein 1/p43: an emerging therapeutic protein working at systems level.

Sang Won Lee1, Gyuyoup Kim, Sunghoon Kim.   

Abstract

BACKGROUND: Drug discovery programs are based on the presumption of one drug-one action-one disease, which is frustrated by the complexity of biological systems. Because the aberration of a single gene often leads to multiple pathological symptoms, we should understand the functional network of the disease-related proteins to develop effective therapy.
OBJECTIVES: To describe how activities of proteins are reflected in phenotypes and their pathological implications using aminoacyl-tRNA synthetase-interacting multi-functional protein 1 (AIMP1).
METHODS: The physiological activities of AIMP1 are unveiled through in vitro approaches and in vivo phenotyptic investigation. Bioinformatics tool was used to combine all AIMP1-target proteins.
CONCLUSION: Although a cytosolic protein, AIMP1 can be secreted as a cytokine to control immune response, angiogenesis and wound healing, and as a glucagon-like hormone for glucose homeostasis. It is involved in the regulation of autoimmune control and TGF-β signaling within the cells. AIMP1-deficient mice developed multiple phenotypes in immune systems, metabolism and body growth. The therapeutic potential of this multi-functional protein with associated biological activities are discussed.

Entities:  

Year:  2008        PMID: 23484969     DOI: 10.1517/17460441.3.8.945

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  5 in total

1.  The N terminus of pro-endothelial monocyte-activating polypeptide II (EMAP II) regulates its binding with the C terminus, arginyl-tRNA synthetase, and neurofilament light protein.

Authors:  Haiming Xu; Nikolay L Malinin; Niranjan Awasthi; Roderich E Schwarz; Margaret A Schwarz
Journal:  J Biol Chem       Date:  2015-02-27       Impact factor: 5.157

2.  Pelizaeus-Merzbacher-like disease caused by AIMP1/p43 homozygous mutation.

Authors:  Miora Feinstein; Barak Markus; Iris Noyman; Hannah Shalev; Hagit Flusser; Ilan Shelef; Keren Liani-Leibson; Zamir Shorer; Idan Cohen; Shareef Khateeb; Sara Sivan; Ohad S Birk
Journal:  Am J Hum Genet       Date:  2010-11-18       Impact factor: 11.025

3.  Identification of gp96 as a novel target for treatment of autoimmune disease in mice.

Authors:  Jung Min Han; Nam Hoon Kwon; Jin Young Lee; Seung Jae Jeong; Hee Jung Jung; Hyeong Rae Kim; Zihai Li; Sunghoon Kim
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

4.  MSC p43 required for axonal development in motor neurons.

Authors:  Xiaodong Zhu; Yang Liu; Yanqing Yin; Aiyun Shao; Bo Zhang; Sunghoon Kim; Jiawei Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-26       Impact factor: 11.205

5.  Amyloid-like oligomerization of AIMP2 contributes to α-synuclein interaction and Lewy-like inclusion.

Authors:  Sangwoo Ham; Seung Pil Yun; Hyojung Kim; Donghoon Kim; Bo Am Seo; Heejeong Kim; Jeong-Yong Shin; Mohamad Aasif Dar; Gum Hwa Lee; Yun Il Lee; Doyeun Kim; Sunghoon Kim; Hee-Seok Kweon; Joo-Ho Shin; Han Seok Ko; Yunjong Lee
Journal:  Sci Transl Med       Date:  2020-11-11       Impact factor: 17.956

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.